RBC Capital sees Biogen stock undervaluing Leqembi prospects
juststock
RBC Capital said it sees Biogen's stock as undervaluing the long-term prospects of its newly approved Alzheimer's drug Leqembi, with any âbetter-than-expected acceleration in demandâ possibly âreigniting enthusiasm and driving upsideâ to the shares. 
The investment bank said in a note dated Aug. 29 that although zuranoloneâs failure to win approval for major depressive disorder was a setback for the company, Biogenâs stock price at $264 âlooks to us to substantially undervalue long-term Leqembi prospects.â 
RBC Capital said that it expects Lequembi sales âto inflect further in the coming months, with increased efficiencies in screening, formularies and monitoring.â It continues to see the product generate sales of $1.4B in 2026, with peak end-user sales of $10.4B by 2032. 
The bank noted that its sales estimates of $1.5M for Q3 and $4.6M for Q4 were below the Streetâs consensus of around $10M for Q3 and $27M for Q4, with the Street expecting a larger near-term inflection. 
RBC Capital has a $357 price target on the stock, with an outperform rating. 

More on Biogen

Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects
Biogen Inc. (NASDAQ:BIIB) Q2 2023 Earnings Call Transcript
Biogen And Alzheimer's Disease: Too Early To Celebrate
Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?
FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri
Biogen's Leqembi set for strong uptake based on Baird physician survey
Sanofi was mystery suitor in Reata Pharma bidding war - report
Biogen/ Sage expected to hike price for new depression drug after narrow label
Seeking Alphaâs Quant Rating on Biogen
Earnings data for Biogen
Dividend for Biogen